Atherosclerosis is characterized by the buildup of plaques within arterial walls, leading to myocardial infarction, which is a leading cause of mortality worldwide. Despite advances in traditional therapies, the multifaceted nature of this condition presents significant challenges. To treat atherosclerosis using the medicine, clinicians and researchers try stabilizing the plaque and reducing the plaque burden. Towards this approach, various drugs and strategies were explored by researchers, and some of them are also in clinical use. Statins were used by cardiologists [1]. To reduce inflammation using many researchers evaluated anti-inflammatory drugs, including rapamycin, Gliclazide [2]. For inhibiting smooth muscle cell migration. However, the bioavailability of these drugs is poor; hence, the drug takes a longer time to produce effects, and many of them exhibit systemic or tissue-specific toxicity. For example, most statins, including simvastatin, show muscle toxicity [5]. To reduce the related toxicity, researchers developed anti-atherosclerotic drug-loaded carriers [4].